MM-163_MedEd2026-Brain
MM-163_CaseClosed-Title

Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects

Activity Description

Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While gastroenterologists and other members of the care team are increasingly aware of new efficacy and safety data, many report uncertainty in selecting, sequencing, and communicating these treatment choices in ways that align with patient preferences, quality-of-life priorities, and long-term disease control.

This fast-paced and highly interactive livestream CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply the latest IL-23 inhibitor data, enhance communication and shared decision-making, and deliver truly patient-centered IBD care.

Notify me when available on demand

Faculty

faculty_RegueiroM
Miguel Regueiro
MD (Moderator)

Chief, Digestive Disease Institute

Cleveland Clinic

Professor, Department of Medicine

Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Cleveland, OH

faculty_AfzaliA
Anita Afzali
MD, MPH, MHCM, FACG, AGAF

Professor of Medicine

Interim Chair, Department of Internal Medicine

University of Cincinnati College of Medicine

Cincinnati, OH

faculty_BarnesE
Edward L. Barnes
MD, MPH

Associate Professor of Medicine

University of North Carolina at Chapel Hill

Chapel Hill, NC

faculty_CollinsA
Angelina Collins
MSN, ANP-BC

Nurse Practitioner

Inflammatory Bowel Disease Center

UC San Diego Health

La Jolla, CA

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Integrate the latest data and guideline recommendations for IL-23 inhibitors into clinical practice as part of treatment selection for patients with IBD
  • Develop treatment plans utilizing effective communication and SDM strategies that factor in patient needs, preferences, QoL considerations, and treatment goals to optimize adherence and long-term outcomes
  • Evaluate the latest clinical trial efficacy and safety data for recently approved IL-23 therapies in IBD
  • Utilize the latest clinical evidence in real-world patient scenarios

Financial Support

Supported by an educational grant from Janssen Scientific Affairs, LLC.

Target Audience

Gastroenterologists, gastroenterology fellows, nurse practitioners (NPs), and physician assistants (PAs)

Credit Information

Jointly_Accredited_Provider_PNG-2
Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


Physicians (ACCME)

CME Outfitters, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nurses (ANCC)

This activity is designated for 2.0 contact hours.
California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 2.0 Contact Hours.


aapa_Cat1_CME_logoPhysician Assistants (AAPA)

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.


accredit-royalMOCRoyal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.


accredit-CME4MIPSMIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.


Certificate of Participation

This activity was certified for a maximum of 2.0 AMA PRA Category 1 Credit(s)™.


ABIM-MOCABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Regueiro reports the following financial relationships:

Advisory Board: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI); Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Organon; Pfizer Inc.; Prometheus Laboratories; Salix Pharmaceuticals; Takeda Pharmaceutical Company Limited; and UCB, Inc.
Consultant: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI); Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Organon; Pfizer Inc.; Prometheus Laboratories; Salix Pharmaceuticals; Takeda Pharmaceutical Company Limited; and UCB, Inc.

Dr. Afzali reports the following financial relationships:

Advisory Board: AbbVie Inc.; Johnson & Johnson; Lilly; Pfizer Inc.; and Takeda Pharmaceutical Company Limited
Consultant: AbbVie Inc.; Johnson & Johnson; Lilly; Pfizer Inc.; Sanofi; and Takeda Pharmaceutical Company Limited
Grants: AbbVie Inc.; Celltrion USA, Inc.; Johnson & Johnson; Lilly; Pfizer Inc.; and Takeda Pharmaceutical Company Limited
Speakers Bureau: AbbVie Inc.; Johnson & Johnson, Pfizer Inc; Takeda Pharmaceutical Company Limited
Other financial or material support: Co-Founder, Board Member of Scrubs & Heels Foundation

Dr. Barnes reports the following financial relationships:

Advisory Board: AbbVie Inc.; Lilly; Pfizer Inc.; and Sanofi
Consultant: Boomerang Medical; Takeda Pharmaceutical Company Limited; and Target RWE
Research Support: Bausch Health Companies, Inc./Salix Pharmaceuticals and Lilly

Ms. Collins reports the following financial relationships:

Advisory Board: AbbVie Inc.; Cristcot; Johnson & Johnson; Lilly; and Takeda Pharmaceutical Company Limited
Consultant: AbbVie Inc.; Cristcot; Johnson & Johnson; Lilly; and Takeda Pharmaceutical Company Limited
Speakers Bureau: AbbVie Inc.; Cristcot; Johnson & Johnson; Lilly; and Takeda Pharmaceutical Company Limited

Peer Reviewers/Planning Committee

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Kashemi D. Rorie, PhD (Planning Committee)
Leah Zadrozny, DVM, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.